vbl
therapeutics
present
wainwright
annual
israel
conference
tel
aviv
israel
globe
newswire
vbl
therapeutics
nasdaq
vblt
biotechnology
company
focused
discovery
development
commercialization
treatments
cancer
today
announces
dror
harats
chief
executive
officer
provide
corporate
overview
format
fireside
chat
analyst
swayampakula
ramakanth
rk
wainwright
annual
israel
conference
held
virtually
november
presentation
details
date
thursday
november
time
eastern
time
webcast
link
archive
recording
available
listening
event
investor
relations
page
vbl
corporate
website
events
vbl
vascular
biogenics
operating
vbl
therapeutics
clinical
stage
biopharmaceutical
company
focused
discovery
development
commercialization
treatments
areas
unmet
need
cancer
immune
inflammatory
indications
vbl
developed
three
platform
technologies
based
technology
targeting
newly
formed
blood
vessels
focus
cancer
technology
targeting
applications
lecinoxoids
family
indications
vbl
lead
oncology
product
candidate
ofranergene
obadenovec
targeted
agent
developed
treat
wide
range
solid
tumors
conveniently
administered
iv
infusion
every
weeks
observed
cancer
patients
demonstrated
activity
signals
comers
phase
trial
well
three
phase
studies
ofranergene
obadenovec
currently
studied
phase
potential
registration
trial
ovarian
cancer
investor
contact
michael
rice
lifesci
advisors
mrice
